DK2216021T3 - Farmaceutisk sammensætning til behandling af overaktiv blære - Google Patents
Farmaceutisk sammensætning til behandling af overaktiv blæreInfo
- Publication number
- DK2216021T3 DK2216021T3 DK08843784.3T DK08843784T DK2216021T3 DK 2216021 T3 DK2216021 T3 DK 2216021T3 DK 08843784 T DK08843784 T DK 08843784T DK 2216021 T3 DK2216021 T3 DK 2216021T3
- Authority
- DK
- Denmark
- Prior art keywords
- overactive
- blower
- treatment
- pharmaceutical composition
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007285802 | 2007-11-02 | ||
PCT/JP2008/069736 WO2009057685A1 (ja) | 2007-11-02 | 2008-10-30 | 過活動膀胱治療用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2216021T3 true DK2216021T3 (da) | 2012-11-05 |
Family
ID=40591069
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK08843784.3T DK2216021T3 (da) | 2007-11-02 | 2008-10-30 | Farmaceutisk sammensætning til behandling af overaktiv blære |
Country Status (12)
Country | Link |
---|---|
US (2) | US20100240697A1 (da) |
EP (1) | EP2216021B1 (da) |
JP (1) | JP5263170B2 (da) |
CA (1) | CA2704298C (da) |
CY (1) | CY1113670T1 (da) |
DK (1) | DK2216021T3 (da) |
ES (1) | ES2393525T3 (da) |
HR (1) | HRP20121078T1 (da) |
PL (1) | PL2216021T3 (da) |
PT (1) | PT2216021E (da) |
SI (1) | SI2216021T1 (da) |
WO (1) | WO2009057685A1 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112013002511A2 (pt) * | 2010-08-03 | 2017-06-27 | Altherx Inc | combinações de agonistas de receptores adrenérgicos beta - 3 e antagonistas receptores muscarínicos para tratamento da bexica hiperativa |
US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
US9522129B2 (en) | 2010-08-03 | 2016-12-20 | Velicept Therapeutics, Inc. | Pharmaceutical Combination |
KR20150045500A (ko) | 2012-08-31 | 2015-04-28 | 아스텔라스세이야쿠 가부시키가이샤 | 경구 투여용 의약 조성물 |
WO2016039367A1 (ja) * | 2014-09-09 | 2016-03-17 | アステラス製薬株式会社 | 尿失禁予防用及び/又は治療用新規医薬組成物 |
CN107205964A (zh) | 2014-12-03 | 2017-09-26 | 威力塞帕特治疗股份有限公司 | 使用调节释放索拉贝隆用于下尿路症状的组合物和方法 |
US10065922B2 (en) | 2015-10-23 | 2018-09-04 | Velicept Therapeutics, Inc. | Solabegron zwitterion and uses thereof |
EP3448366A1 (en) | 2016-04-25 | 2019-03-06 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
EP3448367A1 (en) | 2016-04-25 | 2019-03-06 | Synthon BV | Tablets comprising mirabegron and solifenacin |
US10478399B2 (en) | 2017-10-12 | 2019-11-19 | Synthon B.V. | Modified release tablet composition comprising mirabegron |
WO2022006336A1 (en) * | 2020-07-01 | 2022-01-06 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
EP4159199A1 (en) | 2021-09-29 | 2023-04-05 | Lotus Pharmaceutical Co., Ltd. | Combined formulation of mirabegron and solifenacin |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO2005012I1 (no) * | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
ID23989A (id) | 1997-10-17 | 2000-06-14 | Yamanouchi Pharma Co Ltd | Turunan-turunan amida atau garam-garamnya |
US7342117B2 (en) * | 2001-10-30 | 2008-03-11 | Astellas Pharma Inc. | α-form or β-form crystal of acetanilide derivative |
RU2004135563A (ru) * | 2002-06-07 | 2005-06-10 | Яманоути Фармасьютикал Ко.,Лтд. (Jp) | Лекарственное средство для лечения повышенной активности мочевого пузыря |
ZA200503510B (en) | 2002-11-07 | 2006-12-27 | Yamanouchi Pharma Co Ltd | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
EP1424079A1 (en) * | 2002-11-27 | 2004-06-02 | Boehringer Ingelheim International GmbH | Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine |
EP1539181B1 (en) * | 2003-04-04 | 2007-06-27 | Dynogen Pharmaceuticals Inc. | Method of treating lower urinary tract disorders |
BRPI0416157A (pt) * | 2003-11-03 | 2007-01-09 | Boehringer Ingelheim Int | composição farmacêutica contendo um agonista de adrenoceptor beta-3 e um antagonista alfa e/ou um inibidor de 5-alfa redutase |
CA2560080A1 (en) | 2004-03-16 | 2005-09-22 | Astellas Pharma Inc. | Solifenacin-containing composition |
EP1852117A4 (en) * | 2005-02-25 | 2010-10-27 | Astellas Pharma Inc | PHARMACEUTICAL AGENT COMPRISING SOLIFENACIN |
EP1967202A1 (en) * | 2007-03-05 | 2008-09-10 | AEterna Zentaris GmbH | Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity |
-
2008
- 2008-10-30 EP EP08843784A patent/EP2216021B1/en not_active Revoked
- 2008-10-30 WO PCT/JP2008/069736 patent/WO2009057685A1/ja active Application Filing
- 2008-10-30 SI SI200830841T patent/SI2216021T1/sl unknown
- 2008-10-30 CA CA2704298A patent/CA2704298C/en active Active
- 2008-10-30 PT PT08843784T patent/PT2216021E/pt unknown
- 2008-10-30 PL PL08843784T patent/PL2216021T3/pl unknown
- 2008-10-30 DK DK08843784.3T patent/DK2216021T3/da active
- 2008-10-30 ES ES08843784T patent/ES2393525T3/es active Active
- 2008-10-30 JP JP2009539100A patent/JP5263170B2/ja active Active
- 2008-10-30 US US12/740,699 patent/US20100240697A1/en not_active Abandoned
-
2012
- 2012-12-28 HR HRP20121078AT patent/HRP20121078T1/hr unknown
-
2013
- 2013-01-04 CY CY20131100004T patent/CY1113670T1/el unknown
- 2013-01-24 US US13/748,956 patent/US8772315B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2704298A1 (en) | 2009-05-07 |
PT2216021E (pt) | 2012-11-06 |
ES2393525T3 (es) | 2012-12-26 |
US20100240697A1 (en) | 2010-09-23 |
SI2216021T1 (sl) | 2013-01-31 |
EP2216021A4 (en) | 2010-11-03 |
US20130150402A1 (en) | 2013-06-13 |
PL2216021T3 (pl) | 2013-03-29 |
EP2216021B1 (en) | 2012-10-17 |
EP2216021A1 (en) | 2010-08-11 |
CA2704298C (en) | 2015-07-21 |
CY1113670T1 (el) | 2016-06-22 |
US8772315B2 (en) | 2014-07-08 |
HRP20121078T1 (hr) | 2013-01-31 |
JP5263170B2 (ja) | 2013-08-14 |
WO2009057685A1 (ja) | 2009-05-07 |
JPWO2009057685A1 (ja) | 2011-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
LTC2140867I2 (lt) | Farmacinė kompozicija | |
DK2216021T3 (da) | Farmaceutisk sammensætning til behandling af overaktiv blære | |
DK2474321T3 (da) | Sammensætninger til behandling af collagenmedierede sygdomme | |
DK2154971T3 (da) | Synergistisk farmaceutisk kombination til behandling af cancer | |
DK2478907T3 (da) | Sammensætninger til behandling af kræft | |
DK2504005T3 (da) | Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
DK2220116T3 (da) | Sammensætninger og fremgangsmåder til terapien og diagnosticeringen af influenza | |
DK2137537T3 (da) | Sammensætninger og anvendelser til behandling af multipel sklerose | |
DK3354276T3 (da) | Sammensætninger til behandlingen af gastrointestinal inflammation | |
DK2303330T4 (da) | Farmaceutiske sammensætninger til behandling af parkinsons sygdom | |
DK1868579T3 (da) | Farmaceutisk sammensætning omfattende en omega-carboxyaryl sunstitueret diphenylurea til behandling af cancer | |
DK2796469T3 (da) | Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser | |
DK3456707T3 (da) | 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme | |
DK3492069T3 (da) | Farmaceutiske sammensætninger omfattende jern-oxy-hydroxid | |
BRPI0715712A2 (pt) | Composição farmacêutica | |
DK2114386T3 (da) | Farmaceutisk sammensætning til behandling af diabeteskomplikationer | |
BRPI0719393A2 (pt) | Composição farmacêutica | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
BRPI0716445A2 (pt) | composiÇço farmacÊutica | |
BRPI0720234A2 (pt) | Composição farmacêutica | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
DK2209784T3 (da) | Forbindelser til behandling af hepatitis C | |
BRPI0921313A2 (pt) | composição farmaucêutica |